Gossamer Bio Inc (GOSS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $67.16M
Last updated: Nov 17, 2026 at 4:10 PM ET
Gossamer Bio Inc (GOSS) Statistics
Gossamer Bio (GOSS) has a market cap of $67.16M and an enterprise value of $53.12M. It kept -159.49% of revenue as net income over the last 12 months. Revenue grew 78.03% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 20.90% below the market cap, as cash exceeds debt.
| Market Cap | $67.16M |
|---|---|
| Enterprise Value | $53.12M |
| Latest price (Nov 17, 2026) | $11.04 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 0.9x.
| P/S Ratio | 0.9x |
|---|---|
| Forward P/S | 1.0x |
Price Statistics
The stock is down 94.91% over 52 weeks and trades 5.85% above its 50-day average.
| Beta (1Y) | 2.55 |
|---|---|
| 52-Week Change | -94.91% |
| 1-Month Change | +30.96% |
| 3-Month Change | -11.88% |
| 6-Month Change | -30.69% |
| 5-Year Change | -98.96% |
| Total Return (1Y) | -94.91% |
| Total Return (3Y CAGR) | -44.85% |
| Total Return (5Y CAGR) | -58.66% |
| Return vs SPY (1Y) | -107.03% |
| Max Drawdown (1Y) | -97.22% |
| Max Drawdown (3Y) | -97.22% |
| Sharpe Ratio (1Y) | -1.56 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $10.43 |
| 200-Day Average | $29.44 |
| 52-Week Range | $8.29 to $309.60 |
| RSI (14 Days) | 55.3 |
| Average Volume (20 Days) | 175.65K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.60x current liabilities.
| Current Ratio | 0.60x |
|---|---|
| Quick Ratio | 0.60x |
| Interest Coverage | 4.82x |
Returns and Efficiency
Return on invested capital is 147.40% over the last 12 months, against a 5-year average of -98.16%.
| Return on Assets (ROA) | -194.40% |
|---|---|
| Return on Invested Capital (ROIC) | 147.40% |
| ROA (5Y Average) | -65.35% |
| ROIC (5Y Average) | -98.16% |
| Asset Turnover | 0.57x |
| Receivables Turnover | 25.69x |
Scores
GOSS has an Altman Z-Score of -40.49, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -40.49 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 0 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $78.42M over the last 12 months.
| Revenue | $78.42M |
|---|---|
| Revenue Growth (YoY) | +78.03% |
| Gross Profit | $78.42M |
| Operating Income | -$109.78M |
| Pretax Income | -$125.16M |
| Net Income | -$125.07M |
| Reported EPS (TTM) | -$1.80 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $51.19M |
|---|---|
| Total Debt | $37.15M |
| Net Cash | $14.04M |
| Net Cash Per Share | $2.15 |
| Working Capital | -$39.52M |
| Shareholder Equity | -$122.80M |
| Total Assets | $64.34M |
| Total Liabilities | $187.13M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$156.04M |
|---|---|
| FCF Per Share | -$25.51 |
| Depreciation and Amortization | $6.83M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -139.99%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -139.99% |
| Pretax Margin | -159.60% |
| Net Margin | -159.49% |
Dividends and Yields
GOSS does not pay a dividend.
| Buyback Yield | -33.30% |
|---|---|
| Shareholder Yield | -33.30% |
Stock Splits
The last split was a 1-for-80 reverse split on Sep 11, 2026.
| Last Split Date | Sep 11, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:80 |
Peer Position
Against 7 similar companies, GOSS has the lowest P/S.
P/S RatioPeer median 40.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.27%
| P/S Ratio | 0.9x vs 40.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +78.03% vs +1.27% median |
Analyst Forecast
Consensus estimates put revenue growth at -37.79% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -37.79% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GOSS
What is GOSS's market cap?
Gossamer Bio has a market cap of $67.16M. Its enterprise value, which adds debt and subtracts cash, is $53.12M.
How many shares of GOSS are outstanding?
Gossamer Bio has 6.53M shares outstanding.
Does GOSS pay a dividend?
No. Gossamer Bio does not pay a dividend.
How much debt does GOSS have?
Gossamer Bio has $37.15M of total debt and $51.19M of cash and equivalents, a net cash position of $14.04M.
GOSS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors